CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma

Clinical Study of CD19/CD20 Bispecific Nanobody-derived CAR-T Cells in Refractroy/Relasped B Cell Lymphoma

Evaluation the safety and efficacy of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma

CART cell therapy has become the treatment of choice for patients with relapsed/ refractory B cell lymphoma. Currently, CAR-T cells approved for relapsed/refractory B-cell lymphoma are mainly CAR19-T cells. Nearly half of patients who relapse after treatment with CAR19-T cells are caused by tumor cell antigen escape. Dual-target CAR-T cells targeting CD19 and CD20 may reduce the recurrence rate after treatment. This study was to evaluate the efficacy and safety of CD19/CD20 bispecific CAR-T cells in patients with relapsed/refractory B cell lymphoma.

Inclusion Criteria:

• expected lifetime>3 months
• CD19/CD20 positive relapsed/refractory B cell lymphoma
• KPS>70
• at least one measurable lesion according to RECIST 1.1
• enough function of hear, liver, kidney and bone marrow
• no history of severe allergies
• no other history of malignancy
• no other diseases that conflict with this regimen
• no serious mental illness
• patient or family member sign informed consent

Exclusion Criteria:

• Pregnant or lactating women
• Severe infectious or viral disease
• Active B or C viral hepatitis
• Patients who have used large amounts of glucocorticoids or other immunosuppressive agents during the last 4 weeks
• participated in other clinical studies in the last 3 months, or have been treated with other gene products
• Others not appropriate to participate in this study examined by the investigators